$PLRX
PLIANT THERAPEUTICS, INC.

2023 Q3 Form 10-Q Financial Statement

#000174647323000053 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $248.0K
YoY Change -100.0% -95.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.35M $14.57M
YoY Change 73.98% 75.68%
% of Gross Profit
Research & Development $32.34M $33.00M
YoY Change 31.43% 25.32%
% of Gross Profit
Depreciation & Amortization $500.0K $477.0K
YoY Change 0.0% -4.6%
% of Gross Profit
Operating Expenses $47.69M $47.58M
YoY Change 42.65% 37.38%
Operating Profit -$47.69M -$47.33M
YoY Change 49.26% 59.67%
Interest Expense $317.0K $319.0K
YoY Change -76.2% 232.29%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$41.49M -$41.19M
YoY Change 35.52% 39.42%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$41.49M -$41.19M
YoY Change 35.51% 39.42%
Net Earnings / Revenue -16609.68%
Basic Earnings Per Share -$0.70 -$0.70
Diluted Earnings Per Share -$0.70 -$0.70
COMMON SHARES
Basic Shares Outstanding 59.83M shares 59.16M shares
Diluted Shares Outstanding 59.69M shares 59.17M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $523.6M $555.2M
YoY Change 45.35% 239.35%
Cash & Equivalents $57.68M $54.95M
Short-Term Investments $465.9M $500.2M
Other Short-Term Assets $8.600M $6.520M
YoY Change 106.78% 34.24%
Inventory
Prepaid Expenses
Receivables $0.00 $1.580M
Other Receivables $2.100M $2.442M
Total Short-Term Assets $534.3M $565.7M
YoY Change 46.01% 226.0%
LONG-TERM ASSETS
Property, Plant & Equipment $3.969M $8.518M
YoY Change -17.3% 87.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $392.0K $672.0K
YoY Change -1.26% -26.4%
Total Long-Term Assets $6.129M $9.190M
YoY Change -45.35% -17.15%
TOTAL ASSETS
Total Short-Term Assets $534.3M $565.7M
Total Long-Term Assets $6.129M $9.190M
Total Assets $540.5M $574.9M
YoY Change 43.29% 211.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.360M $2.310M
YoY Change 4.8% -25.87%
Accrued Expenses $8.310M $27.21M
YoY Change -59.08% 56.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $27.40M $29.52M
YoY Change 4.72% 30.89%
LONG-TERM LIABILITIES
Long-Term Debt $10.00M $9.988M
YoY Change -28.7% -30.05%
Other Long-Term Liabilities $0.00 $2.318M
YoY Change -100.0% -47.4%
Total Long-Term Liabilities $10.00M $12.31M
YoY Change -28.7% -13.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.40M $29.52M
Total Long-Term Liabilities $10.00M $12.31M
Total Liabilities $37.42M $41.83M
YoY Change -6.9% 13.56%
SHAREHOLDERS EQUITY
Retained Earnings -$458.6M -$417.2M
YoY Change 51.19% 52.95%
Common Stock $963.6M $952.5M
YoY Change 49.91% 125.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $503.0M $533.1M
YoY Change
Total Liabilities & Shareholders Equity $540.5M $574.9M
YoY Change 43.29% 211.39%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$41.49M -$41.19M
YoY Change 35.51% 39.42%
Depreciation, Depletion And Amortization $500.0K $477.0K
YoY Change 0.0% -4.6%
Cash From Operating Activities -$36.22M -$24.76M
YoY Change 95.8% 1.49%
INVESTING ACTIVITIES
Capital Expenditures $90.00K $603.0K
YoY Change -112.93% -337.4%
Acquisitions
YoY Change
Other Investing Activities $38.35M -$22.38M
YoY Change -121.6% -431.53%
Cash From Investing Activities $38.26M -$22.98M
YoY Change -121.46% -453.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 700.0K 161.0K
YoY Change -99.68% -98.46%
NET CHANGE
Cash From Operating Activities -36.22M -24.76M
Cash From Investing Activities 38.26M -22.98M
Cash From Financing Activities 700.0K 161.0K
Net Change In Cash 2.740M -47.58M
YoY Change -85.98% 536.47%
FREE CASH FLOW
Cash From Operating Activities -$36.22M -$24.76M
Capital Expenditures $90.00K $603.0K
Free Cash Flow -$36.31M -$25.36M
YoY Change 103.97% 5.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59222685 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59222685 shares
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41192000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-41192000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29546000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-29546000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-78740000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-78740000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36144944 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36144944 shares
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3661000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
334000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
199059000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3531000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-749000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-28100000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
173793000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
446000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3403000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-309000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-29546000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
147788000 usd
us-gaap Net Income Loss
NetIncomeLoss
-78740000 usd
us-gaap Net Income Loss
NetIncomeLoss
-57646000 usd
us-gaap Depreciation
Depreciation
929000 usd
us-gaap Depreciation
Depreciation
914000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
24969000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6934000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1236000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
684000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
6512000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-443000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-403000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2991000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1809000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1907000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
738000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
202000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5087000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5404000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1336000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-745000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55035000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44894000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
411096000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
78048000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
214676000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
86972000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
766000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
898000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-197186000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8026000 usd
plrx Proceeds From Issuances Of Common Stock Under Benefit Plans
ProceedsFromIssuancesOfCommonStockUnderBenefitPlans
3995000 usd
plrx Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
759000 usd
plrx Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
75000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
150000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
270251000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
273487000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10273000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21266000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26595000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33685000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51665000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54951000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25070000 usd
us-gaap Interest Paid Net
InterestPaidNet
570000 usd
us-gaap Interest Paid Net
InterestPaidNet
72000 usd
plrx Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting
ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting
0 usd
plrx Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting
ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting
1000 usd
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11435241 shares
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
550259000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2245000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
548018000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
327771000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
45000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2003000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
325813000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12102000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11327000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7770000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6841000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4332000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4486000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
400000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
400000 usd
us-gaap Depreciation
Depreciation
900000 usd
us-gaap Depreciation
Depreciation
900000 usd
CY2023Q2 plrx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
4402000 usd
CY2022Q4 plrx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
3421000 usd
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
451000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1427000 usd
CY2023Q2 plrx Prepaid Licenses Current
PrepaidLicensesCurrent
1438000 usd
CY2022Q4 plrx Prepaid Licenses Current
PrepaidLicensesCurrent
959000 usd
CY2023Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
2365000 usd
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1078000 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
229000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
173000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8885000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7058000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5747000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7200000 usd
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1015000 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1458000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6762000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8658000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24969000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5455000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4545000 usd
CY2023Q2 plrx Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
0 usd
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000 usd
CY2023Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
121000 usd
CY2023Q2 plrx Long Term Debt Accretion Of Final Payment
LongTermDebtAccretionOfFinalPayment
109000 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
9988000 usd
CY2023Q2 plrx Number Of Classes Of Stock Authorized
NumberOfClassesOfStockAuthorized
2 class
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of shares of common stock are entitled to one vote for each share of common stock held at any meeting of stockholders.
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14243303 shares
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3403000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13046000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6934000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 plrx Valuation Allowance As Percentage On Deferred Tax Assets
ValuationAllowanceAsPercentageOnDeferredTaxAssets
1
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
plrx Contractual Arrangements Cancellation Period
ContractualArrangementsCancellationPeriod
P30D
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000 usd
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7794146 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5420264 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-41192000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-29546000 usd
us-gaap Net Income Loss
NetIncomeLoss
-78740000 usd
us-gaap Net Income Loss
NetIncomeLoss
-57646000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-41192000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41192000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29546000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-29546000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-78740000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-78740000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-78740000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-78740000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-57646000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-57646000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59172869 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59172869 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36173135 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36173135 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57623842 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57623842 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36144944 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36144944 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.59

Files In Submission

Name View Source Status
0001746473-23-000053-index-headers.html Edgar Link pending
0001746473-23-000053-index.html Edgar Link pending
0001746473-23-000053.txt Edgar Link pending
0001746473-23-000053-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plrx-20230630.htm Edgar Link pending
plrx-20230630.xsd Edgar Link pending
plrx-20230630xex311.htm Edgar Link pending
plrx-20230630xex312.htm Edgar Link pending
plrx-20230630xex321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
plrx-20230630_cal.xml Edgar Link unprocessable
plrx-20230630_def.xml Edgar Link unprocessable
plrx-20230630_lab.xml Edgar Link unprocessable
plrx-20230630_pre.xml Edgar Link unprocessable
plrx-20230630_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable